NCT03843294View on ClinicalTrials.gov

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

May 2, 2023

Study Completion Date

August 31, 2026

Conditions
Hodgkin LymphomaDiffuse Large B Cell Lymphoma
Interventions
BIOLOGICAL

TAA-T cells

The patient will receive two TAA-T cell infusions given 2 weeks apart. TAA-T cell dose: 2 x 107 cells/m2.per infusion.

DRUG

Nivolumab

Nivolumab: For patients \<18 years, 3 mg/kg/dose (maximum 240mg/dose) every 2 weeks. For adult patients ≥18 years, a dose of 240mg every 2 weeks or 480mg every 4 weeks

Trial Locations (1)

84112

Utah University School of Medicine/Huntsman Cancer Institute, Salt Lake City

All Listed Sponsors
lead

Catherine Bollard

OTHER